Glucose levels 2 h after an oral glucose challenge are a clinical measure of glucose tolerance used in the diagnosis of type 2 diabetes. We report a meta-analysis of nine genome-wide association studies (n = 15,234 nondiabetic individuals) and a follow-up of 29 independent loci (n = 6,958–30,620). We identify variants at the GIPR locus associated with 2-h glucose level (rs10423928, β (s.e.m.) = 0.09 (0.01) mmol/l per A allele, P = 2.0 × 10−15). The GIPR A-allele carriers also showed decreased insulin secretion (n = 22,492; insulinogenic index, P = 1.0 × 10−17; ratio of insulin to glucose area under the curve, P = 1.3 × 10−16) and diminished incretin effect (n = 804; P = 4.3 × 10−4). We also identified variants at ADCY5 (rs2877716, P = 4.2 × 10−16), VPS13C (rs17271305, P = 4.1 × 10−8), GCKR (rs1260326, P = 7.1 × 10−11) and TCF7L2 (rs7903146, P = 4.2 × 10−10) associated with 2-h glucose. Of the three newly implicated loci (GIPR, ADCY5 and VPS13C), only ADCY5 was found to be associated with type 2 diabetes in collaborating studies (n = 35,869 cases, 89,798 controls, OR = 1.12, 95% CI 1.09–1.15, P = 4.8 × 10−18).
At a glance
- Type 2 diabetes: new genes, new understanding. Trends Genet. 24, 613–621 (2008). , &
- A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat. Genet. 41, 89–94 (2009). et al.
- A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320, 1085–1088 (2008). et al.
- Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J. Clin. Invest. 118, 2620–2628 (2008). et al.
- Variants in MTNR1B influence fasting glucose levels. Nat. Genet. 41, 77–81 (2009). et al.
- Novel genetic loci implicated in fasting glucose homeostasis and their impact on related metabolic traits. Nat. Genet. advance online publication, doi:10.1038/ng.520 (17 January 2010). et al.
- Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 164, 2090–2095 (2004). et al.
- Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46 Suppl 1, M17–M21 (2003). , &
- Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25, 1845–1850 (2002). , , &
- Twin study of genetic and environmental influences on glucose tolerance and indices of insulin sensitivity and secretion. Diabetologia 46, 1276–1283 (2003). et al.
- Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112–3121 (2008). et al.
- Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320–323 (2006). et al.
- Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985). et al.
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab. 34 Suppl 2, S65–S72 (2008). , &
- Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63, 492–498 (1986). et al.
- Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur. J. Endocrinol. 150, 97–104 (2004). &
- Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 117, 2155–2163 (2007). et al.
- Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51, 502–511 (2008). et al.
- Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. USA 96, 14843–14847 (1999). et al.
- Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41, 1194–1198 (1998). et al.
- Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45, 1701–1705 (1996). et al.
- Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol. Nutr. Food Res. 51, 1046–1052 (2007). et al.
- Genomewide association studies and human disease. N. Engl. J. Med. 360, 1759–1768 (2009). &
- The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117, 24–32 (2007).
- Expression of adenylyl cyclase subtypes in pancreatic beta-cells. Biochem. Biophys. Res. Commun. 254, 703–706 (1999). , &
- Analysis of the human VPS13 gene family. Genomics 84, 536–549 (2004). , , , &
- The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51, 70–75 (2008). et al.
- The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40, 984–986 (1997). , &
- Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50, 2497–2504 (2001). et al.
- A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39, 906–913 (2007). , , , &
- Mach 1.0: rapid haplotype reconstruction and missing genotype inference. Am. J. Hum. Genet. S79, 2290 (2006). , &
- Evaluating and improving power in whole-genome association studies using fixed marker sets. Nat. Genet. 38, 663–667 (2006). et al.
- Analysis of serial measurements in medical research. Br. Med. J. 300, 230–235 (1990). , , &
- Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care 21, 949–958 (1998). et al.
- The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48, 608–611 (2005). &
- Supplementary Text and Figures (976K)
Supplementary Figure 1, Supplementary Tables 2–6 and Supplementary Note
- Supplementary Table 1 (84K)
Cohort and study characteristics and details of analysis metrics and methods
- Supplementary Table 2 (60K)
Meta-analysis of association results for 2-hr glucose across discovery and replication cohorts
- Supplementary Table 4 (48K)
Association of rs10423928 [GIPR], rs17271305 [VPS13C] and rs2877716 [ADCY5] with insulinogenic index, AUC (area under the curve) insulin/glucose, and 2h insulin (adjusted for 2h glucose) within MAGIC and meta-analysis across all studies